• Natera entered a Signatera collaboration with Angiex to track treatment response in Angiex’s Phase I AGX101 solid-tumor trial.
• Agreement calls for longitudinal Signatera ctDNA testing during AGX101 dosing to assess molecular response alongside imaging.
• AGX101 targets TM4SF1 to deliver a cytotoxic payload to tumor cells, also tumor-associated endothelial cells, aiming to hit tumor vasculature.
• Data are intended to support development decisions for AGX101 by clarifying response when radiology results are uncertain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608270600BIZWIRE_USPR_____20260827_BW232786) on August 27, 2026, and is solely responsible for the information contained therein.